Publication | Closed Access

Phase III, randomized, placebo-controlled study of once-daily oral zibotentan (ZD4054) in patients with non-metastatic castration-resistant prostate cancer

UrologyGenitourinary CancerMedicinePhase IiiOnce-daily Oral ZibotentanClinical TrialsPlacebo-controlled StudyPharmacotherapyCancer TreatmentProstatic DiseaseOncology